+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Comparison of teprenone and famotidine against gastroduodenal mucosal damage in patients taking low-dose aspirin



Comparison of teprenone and famotidine against gastroduodenal mucosal damage in patients taking low-dose aspirin



Journal of Gastroenterology and Hepatology 29 Suppl 4: 11-15



Proton-pump inhibitors are known to be effective in the treatment and prevention of ulcers related to low-dose aspirin (LDA), but few reports address H2 -receptor antagonists (H2RAs) and gastroprotective agents (GPs). This study was intended to compare the therapeutic effects of an H2RA and a GP against gastroduodenal mucosal injuries in patients taking LDA. The subjects consisted of patients requiring continuous LDA treatment, in whom no peptic ulcer was found on endoscopy at enrollment. The patients were randomized to either famotidine 20 mg/day (group F) or teprenone 150 mg/day (group T). The study medication was administered for 12 weeks. The patients underwent endoscopy after administration of the study medication in order to obtain a Lanza score. A total of 66 patients (38 in group F, 28 in group T) were included in the efficacy analysis population. The Lanza score changed as follows: in group F, it improved significantly, from 0.89±1.03 (mean±standard deviation) before medication to 0.39±0.75 after medication (P=0.006); in group T, no significant difference was observed: 0.75±0.93 before medication and 0.68±0.82 after medication. Famotidine is better than teprenone in terms of reducing the number of the erosions under use of LDA.

(PDF emailed within 0-6 h: $19.90)

Accession: 057471253

Download citation: RISBibTeXText

PMID: 25521726

DOI: 10.1111/jgh.12768


Related references

Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2. Bmc Research Notes 6: 116-116, 2013

Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs: possible effect of rebamipide. Journal of Clinical Biochemistry and Nutrition 47(1): 27-31, 2010

Ranitidine protects against gastroduodenal mucosal damage associated with low dose aspirin therapy. Zeitschrift fuer Gastroenterologie 27(12): 722-724, 1989

Effect of aspirin cessation before endoscopy in Japanese patients with low-dose-aspirin-associated gastroduodenal mucosal injury. United European Gastroenterology Journal 1(4): 259-264, 2014

Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Alimentary Pharmacology and Therapeutics 31(1): 143-149, 2010

Prevention of gastroduodenal complications in patients taking low-dose aspirin. Gastroenterologie Clinique et Biologique 28 Spec No 3: C84-C89, 2004

Comparison of effects of calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers. Gut 38(1): 11-14, 1996

Salicylsalicylic acid causes less gastroduodenal mucosal damage than enteric-coated aspirin. An endoscopic comparison. Digestive Diseases and Sciences 34(2): 229-232, 1989

Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage. Scandinavian Journal of Gastroenterology 45(3): 292-298, 2010

Clinical features of gastroduodenal ulcer in Japanese patients taking low-dose aspirin. Digestive Diseases and Sciences 55(8): 2270-2274, 2010

Predictors of gastroduodenal erosions in patients taking low dose aspirin h pylori protects the stomach but not the duodenum. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No 801, 2003

Low-dose aspirin-induced gastroduodenal mucosal injury in Japanese patients with arteriosclerotic disease. Internal Medicine 49(23): 2537-2545, 2011

Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374(9684): 119-125, 2009

Investigation of gastroduodenal mucosal injuries caused by low-dose aspirin therapy in patients with cerebral infarction. Journal of Gastroenterology and Hepatology 25 Suppl 1: S119-S121, 2010

Endoscopic survey of low-dose-aspirin-induced gastroduodenal mucosal injuries in patients with ischemic heart disease. Journal of Gastroenterology and Hepatology 23 Suppl 2: S234-S236, 2009